Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Reports outline acute myeloid leukemia study results from P. Chevallier et al
December 30th, 2008
According to recent research published in the Journal of Clinical Oncology, " To determine the antitumor activity and safety of a combination of gemtuzumab ozogamicin (GO), intermediate-dose cytarabine, and mitoxantrone (MIDAM) in patients with refractory or relapsed CD33(+) acute myeloid leukemia (AML). Patients and Methods We treated 62 patients with refractory (n = 18) or relapsed (n = 44) CD33(+) AML." "Median age was 55.5 years. Salvage regimen consisted of GO 9 mg/m(2) on day 4, cytarabine 1 g/m(2) every 12 hours on days 1 through 5, and mitoxantrone 12 mg/m(2)/d on days 1 through 3. Median follow-up time was 26.5 months. Thirty-one patients (50%) achieved...
Source: Cancer Weekly (2008-12-30)
|
